The FDA has granted fast-track designation to Prima BioMed's experimental drug CVac as a treatment for relapsed platinum-sensitive epithelial ovarian cancer. The drug also holds orphan drug status in both the U.S. and Europe. The designation is an "important milestone" for Prima and a "recognition of the serious nature of ovarian cancer and the clear unmet medical need to develop new treatments for relapsed platinum-sensitive ovarian cancer in remission," CEO Matthew Lehman said.

Related Summaries